Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  07/31/2007
 
STEPAN COMPANY
(Exact name of registrant as specified in its charter)
 
Commission File Number:  1-4462
 
Delaware
  
36-1823834
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
Edens and Winnetka Road, Northfield, Illinois 60093
(Address of principal executive offices, including zip code)
 
(847)446-7500
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Information to be included in the report

 
Item 2.02.    Results of Operations and Financial Condition
 
On July 31, 2007, Stepan Company ("Stepan") issued a press release providing its financial results for the second quarter ended June 30, 2007. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
 
 
Item 9.01.    Financial Statements and Exhibits
 
(c) Exhibits

    Exhibit Number: 99.1

    Description: Press Release of Stepan Company dated July 31, 2007

 

 

Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
STEPAN COMPANY
 
 
Date: August 02, 2007
     
By:
 
/s/    Kathleen M. Owens

               
Kathleen M. Owens
               
Assistant Secretary
 
 


 

Exhibit Index
 
Exhibit No.

  
Description

EX-99.1
  
Press Release of Stepan Company dated July 31, 2007
DC2321.pdf -- Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing

FOR IMMEDIATE RELEASE: CONTACT: JAMES E. HURLBUTT (847) 446-7500

STEPAN REPORTS HIGHER SECOND QUARTER AND FIRST HALF SALES AND EARNINGS

     NORTHFIELD, Illinois, July 31, 2007 -- Stepan Company (NYSE: SCL) today reported second quarter results for the period ended June 30, 2007.

SUMMARY                                 
    Three Months Ended June 30    Six Months Ended June 30 


($ in thousands)                %                % 
       2007    2006    Change       2007    2006    Change 
 
Net Sales    $336,156    $292,033    +    15    $649,160    $581,645    +    12 
 
Net Income    4,737    3,077    +    54    10,424    6,126    +    70 
 
Earnings per Diluted Share    $0.47    $0.31    +    52    $1.03    $0.62    +    66 

SECOND QUARTER RESULTS

Net income for the quarter was $4.7 million, or $0.47 per diluted share, compared to $3.1 million, or $0.31 per diluted share, a year ago. Gross profit rose by $5.0 million, or 15 percent, due to a nine percent increase in volume. The surfactant and polymer segments both recorded improved gross profit on higher volumes.

Pretax income of $7.5 million was up $3.1 million, or 69 percent. Following is a reconciliation of pretax income excluding certain significant quarterly and year-to-date items.


    Three Months Ended June 30    Six Months Ended June 30 


($ in thousands)    2007    2006    2007    2006 
Reported Pretax Income    $7,459    $4,404    $15,539    $8,569 
(Gain) on Sale of Product Line    (4,290)        (4,290)     
Goodwill Impairment Charge    3,467        3,467     
Deferred Compensation Expense    1,995    916    631    2,580 
Pretax Income Excluding Significant Items    $8,631    $5,320    $15,347    $11,149 

As previously reported, the Company sold its specialty ester personal care surfactant product line on April 30, 2007. The business represented approximately $15 million in annual net sales. The sale proceeds included cash plus the transfer to Stepan of a specialty agricultural surfactant product line. The Company contractually agreed to produce product for the buyer for up to one year. The $4.3 million pretax gain is net of costs associated with the manufacturing agreement, write-downs for equipment and inventory and severance charges.

The Company also recorded a non-cash goodwill impairment charge of $3.5 million. The Company tests its goodwill for impairment in the second quarter of each year in accordance with generally accepted accounting principles. The Company concluded that the entire goodwill related to its subsidiary in the United Kingdom was impaired as a result of lower discounted cash flow forecasts from the business.

Also affecting the quarter was deferred compensation expense of $2.0 million compared to $0.9 million of expense in the year ago quarter due to stock market appreciation. The accounting requirement for the Company’s deferred compensation plan results in expense when the price of Stepan Company stock or mutual funds held for the plan rise and income when they decline.

Net sales increased 15 percent during the quarter due to higher volume (9%), higher selling prices (4%) and the impact of foreign exchange (2%).

YEAR-TO-DATE RESULTS

Net income for the six month period was $10.4 million, or $1.03 per diluted share, compared to $6.1 million, or $0.62 per diluted share, last year. Gross profit increased $7.5 million, or 11 percent, due to improved surfactant and polymer sales volume. Pretax income rose $7.0 million (81 percent) due to improved operating results in all segments and lower deferred compensation expense. See discussion on the following page.

Year-to-date net sales increased 12 percent due to higher volume (9%), foreign exchange impact (2%) and selling prices (1%).

2


SEGMENT RESULTS                                 
 
    Three Months Ended June 30    Six Months Ended June 30 


($ in thousands)                %                % 
       2007    2006    Change    2007    2006    Change 
 
Net Sales                                 
     Surfactants    $242,765    $219,089     +    11    $479,241    $444,366    + 8 
     Polymers    84,892    64,989     +    31    153,574    122,881     +    25 
     Specialty Products    8,499    7,955    + 7    16,345    14,398     +    14 




Total Net Sales    $336,156    $292,033     +    15    $649,160    $581,645     +    12 



An eight percent surfactant sales volume improvement led to a $2.8 million (13 percent) improvement in surfactant gross profit, excluding the gain from the product line sale. Most of the volume and gross profit improvement occurred in North America across all product lines except for biodiesel, which experienced lower profitability. Higher raw material costs for biodiesel have led to lower profit margins. European surfactant volume and gross profit improved by 11 percent and 17 percent, respectively. The plant in France has changed from a five to a seven day a week operation creating increased capacity to accommodate higher sales demand. Excluding the $3.5 million U.K. goodwill impairment charge, European gross profit improved slightly. Latin America reported lower gross profit as Mexico experienced lower profit margins on fabric softener due to rising raw material costs and outsourcing costs as demand exceeded capacity. A new reactor in Mexico was placed into service during the quarter, which should eliminate outsourcing costs.

Polymer gross profit grew by $1.9 million (18 percent) driven by global polyol volume. A 51 percent increase in European polyol volume combined with margin improvement offset the decline in North America polyol profitability due to lower margins. The polyol joint venture in China had a small loss due to higher raw material costs. Volume in China grew by 29 percent.

Specialty products gross profit was relatively unchanged as improvement in food ingredient profitability was offset by weaker pharmaceutical profits.

OPERATING EXPENSES                             
 
    Three Months Ended June 30    Six Months Ended June 30 



($ in thousands)            %                % 
     2007    2006    Change     2007    2006    Change 
 
Marketing    $9,109    $8,556    + 6    $18,041    $16,998     +    6 
Administrative – General    9,520    9,500        18,600    18,369     +    1 
Administrative – Deferred                             
 Compensation Obligations    1,995    916    NM    631    2,580    NM 
Research, development                             
and technical service    7,954    7,313    + 9    15,583    14,493     +    8 


Total    $28,578    $26,285    + 9    $52,855    $52,440     +    1 

3


Excluding deferred compensation expense, operating expenses rose five percent for both the three and six month periods. Higher marketing and research costs were largely attributable to salary and benefit costs.

OTHER INCOME AND EXPENSE

Interest expense grew by 15 percent due to higher average debt levels brought about by higher working capital requirements. Working capital requirements have grown due to improved sales volume and the impact of rising raw material costs. The loss from our equity in the Philippine joint venture increased slightly. The Philippine fabric softener product line continues to improve in profitability, while commodity laundry products are generating a loss.

PROVISION FOR INCOME TAXES

The effective tax rate rose to 37.6 percent for the quarter compared to 30.7 percent a year ago. The increase in the effective tax rate was primarily due to the recording of Stepan U.K. goodwill impairment for which no tax benefit was realized. This was partially offset by a reduction in the tax provision attributable to the recognition of German tax loss carryforward benefits.

OUTLOOK

“Global polyol and North American surfactants should continue to drive profit improvement in the second half,” said F. Quinn Stepan, Jr., President and Chief Executive Officer. “We have taken steps to improve our profitability going forward. The sale of the personal care ester product line will lead to improved results from our Maywood, New Jersey plant. Last year’s downsizing and anticipated volume growth should improve profits in Europe. In July, we negotiated a new labor agreement for Millsdale, our largest manufacturing site, which includes freezing the current defined benefit plan and replacing it with a defined contribution plan. This change is consistent with those implemented in 2006 for most of the U.S. workforce. One time costs associated with the retirement plan changes, estimated to be $1.4 million pretax, will be incurred in the third quarter. Plans to expand biodiesel capacity are on hold,” said Mr. Stepan.

“We have recently introduced several new technologies to the market, including our next generation polyol, which should favorably impact earnings in 2008. For the current year, we are on track to deliver significant earnings improvement over 2006,” said Mr. Stepan.

4


CONFERENCE CALL

Stepan Company will host a conference call to discuss the second quarter results at 2:00 p.m. Eastern Daylight Time on August 1, 2007. To listen to a live webcast of this call, please go to our Internet website at: www.stepan.com, click on investor relations, next click on conference calls and follow the directions on the screen.

Stepan Company, headquartered in Northfield, Illinois, is a leading producer of specialty and intermediate chemicals used in household, industrial, personal care, agricultural, food and insulation related products. The common and the convertible preferred stocks are traded on the New York and Chicago Stock Exchanges under the symbols SCL and SCLPR.

* * * * *
table follows

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Stepan Company’s Form 10-K, Form 8-K and Form 10-Q reports and exhibits to those reports, and include (but are not limited to), prospects for our foreign operations, foreign currency fluctuations, certain global and regional economic conditions, the probability of future acquisitions and the uncertainties related to the integration of acquired businesses, the probability of new products, the loss of one or more key customer or supplier relationships, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic conditions. These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

5


STEPAN COMPANY
Statements of Income
For the Three and Six Months Ended June 30, 2007 and 2006
(Unaudited – 000’s Omitted)
 
 
    Three Months Ended        Six Months Ended     
        June 30                June 30         








                %                % 
         2007         2006    Change       2007         2006    Change 
 
 
 
Net Sales    $336,156    $292,033    +    15    $649,160    $581,645     +    12 
Cost of Sales    297,882    258,789    +    15    576,077    516,067     +    12 
   Gross Profit    38,274    33,244    +    15    73,083    65,578     +    11 
 
Operating Expenses:                                 
   Marketing    9,109    8,556    +    6    18,041    16,998     +    6 
   Administrative    11,515    10,416    +    11    19,231    20,949     -    8 
   Research, development                                 
and technical services    7,954    7,313    +    9    15,583    14,493     +    8 
    28,578    26,285    +    9    52,855    52,440     +    1 
 
   Gain on sale of product line    (4,290)        +    -    (4,290)         +    - 
   Goodwill Impairment Charge    3,467        +    -    3,467         +    - 
 
Operating Income    10,519    6,959    +    51    21,051    13,138     +    60 
Other Income (Expense):                                 
   Interest, net    (2,515)    (2,179)    +    15    (4,823)    (4,240)     +    14 
   Loss from equity in Joint Venture    (10)    (8)    +    25    (136)    (103)     +    32 
   Other, net    (535)    (368)    +    45    (553)    (226)     +    145 
    (3,060)    (2,555)    +    20    (5,512)    (4,569)     +    21 
 
Income Before Income Taxes                                 
and Minority Interest    7,459    4,404    +    69    15,539    8,569     +    81 
 
Provision for Income Taxes    2,805    1,352    +    107    5,199    2,518     +    106 
 
Minority Interest    (83)    (25)    +    232    (84)    (75)     +    12 
 
Net Income    $4,737    $3,077    +    54    $10,424    $6,126     +    70 
 
Net Income Per Common Share                                 
   Basic    $0.49    $0.32    +    53    $1.08    $0.63     +    71 
   Diluted    $0.47    $0.31    +    52    $1.03    $0.62     +    66 
 
Shares Used to Compute Net                                 
Income Per Common Share                                 
   Basic    9,304    9,124    +    2    9,298    9,085     +    2 
   Diluted    10,085    9,957    +    1    10,079    9,886     +    2 

6